Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease

NCT05343364 is registered in ClinicalTrials.gov with Phathom Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05343364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05343364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Lead sponsor
Phathom Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 9, 2022
Completion date
June 13, 2023
Enrollment
24 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux